Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment

Abstract

The Agenzia Italiana del Farmaco (Aifa) and the Italian Ministry of Health authorized the fourth dose of the BNT162b2 vaccine (BioNTech/Pfizer) to subjects with a marked impairment of the immune response from 1 March 2022.1Available at.https://www.salute.gov.it/imgs/C_17_pagineAree_5452_43_file.pdfDate accessed: May 29, 2022Google Scholar Immunocompromised patients have heterogeneous levels of immunosuppression, with subsequent heterogeneous vaccine responses.2See K.C. Vaccination for the prevention of infection among immunocompromised patients: a concise review of recent systematic reviews.Vaccines (Basel). 2022; 10: 800Crossref PubMed Scopus (3) Google Scholar Knowledge of these differences between various patients’ subgroups may improve the preventive measures. We characterized the humoral and cellular immune responses before and after the fourth BNT162b2 vaccine dose in patients with solid tumors. The current analysis included 23 patients with solid tumors (6 females, 17 males; median age 66 years, range 48-86 years) who were on active treatment at the time of the fourth dose. Lung cancer (82%) was the most common tumor subtype. Twenty-one patients (91%) were on immunotherapy alone and two patients (9%) were on chemo-immunotherapy (Supplementary Table S1, available at https://doi.org/10.1016/j.annonc.2022.07.012). We have considered only patients without a documented previous COVID-19 infection to exclude the confounder of ‘hybrid immunity’. Patients received the fourth BNT162b2 vaccine dose 6 months after their third dose. The most common side-effect was pain at the injection site (65.2%). Nobody had grade 3-4 side-effects (Supplementary Table S2, available at https://doi.org/10.1016/j.annonc.2022.07.012). Three weeks after the fourth dose, all subjects except one (on anti-programmed cell death protein 1) developed positive levels of anti-spike antibodies. A significant difference was detected between the baseline, median 1020 [interquartile range (IQR) 456-2020] BAU/ml and 3 weeks after the fourth dose, when the majority of patients (82.6%) reached levels >2080 BAU/ml (P = 0.006) (Figure 1A). As regards neutralizing antibodies titer 3 weeks after the fourth dose, the percentage of responders against wild type (WT) strain was 91% (21/23) and the median titer was 1 : 320 (IQR 1 : 40-1 : 640). Before the fourth dose, positive values were detected in 22/23 patients and the median titer was 1 : 640 (IQR 1 : 320-1 : 640). No difference between the baseline and 3 weeks after the fourth dose was detected (Figure 1B). At the baseline, the percentage of responders against the Omicron strain was 73% (17/23) and 95% (22/23) after the fourth dose, respectively. A significant difference between the baseline and 3 weeks after the fourth dose was observed [median 1 : 10 (IQR <1 : 10-1 : 160) versus 1 : 160 (IQR 1 : 40-1 : 640); P < 0.0001] (Figure 1B). A significant difference between WT and Omicron was detected, not only 3 weeks after the fourth dose (P < 0.0001) but also before (P = 0.0363). The percentage of subjects with positive T-cell response was 65% before and 90% after the fourth dose (P = 0.1914). The median level of response was higher at 3 weeks after the fourth dose, but this difference was not statistically significant (P = 0.1415; Figure 1C). The third dose is able to reinforce anti-COVID-19 immunity in patients with cancer,3Shapiro L.C. Thakkar A. Campbell S.T. et al.Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer.Cancer Cell. 2021; 40: 3-5Abstract Full Text Full Text PDF PubMed Scopus (42) Google Scholar but the duration of protection is difficult to predict, because the exact mechanisms of protective immunity against SARS-CoV-2 are unknown yet. Our data suggest that the fourth dose may increase the vaccine effectiveness also against the Omicron variant. Future larger studies are warranted to confirm our results. Finally, repeated booster vaccination in patients with solid tumors on active treatment appears without any safety concerns, as previously reported by Waissengrin et al.4Waissengrin B. Agbarya A. Safadi E. Padova H. Wolf I. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors.Lancet Oncol. 2021; 22: 581-583Abstract Full Text Full Text PDF PubMed Scopus (111) Google Scholar